(NASDAQ: TLSI) Trisalus Life Sciences's forecast annual revenue growth rate of 32.98% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.26%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Trisalus Life Sciences's revenue in 2026 is $45,077,000.On average, 7 Wall Street analysts forecast TLSI's revenue for 2026 to be $3,336,111,828, with the lowest TLSI revenue forecast at $2,962,846,603, and the highest TLSI revenue forecast at $3,589,245,009. On average, 7 Wall Street analysts forecast TLSI's revenue for 2027 to be $4,672,342,223, with the lowest TLSI revenue forecast at $4,230,051,871, and the highest TLSI revenue forecast at $5,284,455,321.
In 2028, TLSI is forecast to generate $6,526,907,600 in revenue, with the lowest revenue forecast at $5,699,652,849 and the highest revenue forecast at $7,325,530,162.